Introduction
The work of Huggins and colleagues in the 1940s established the hormonal dependency of prostate cancer. 1 The potential importance of adrenal androgens was ®rst recognized in 1945 and limited success was achieved by performing bilateral adrenalectomy in men with relapsed prostate cancer following orchiectomy, although the procedure was associated with considerable morbidity. 2 More recently, it has been shown that castration ablates testicular production of testosterone, suppressing serum levels by 90 ± 95%. Nevertheless, intraprostatic levels of dihydrotestosterone (DHT) may remain at 40% of control levels, 3 re¯ecting the conversion of adrenal androgens (androstenedione and dehydroepiandrosterone (DHEA) to DHT within the prostate cells themselves.
Currently, treatment of metastatic disease with androgen deprivation has been shown to produce clinical response rates of 70 ± 80%. 4 However, relapse of the prostate cancer to a hormone refractory state may occur in the ®rst 2 y of treatment and is associated with a subsequent average life expectancy of under 12 months. 4, 5 In terms of patients presenting with advanced prostate cancer, data indicate that, although the percentages are decreasing, they are still signi®cant. A study reviewing 1090 patients over the 10 y period 1985 ± 1994 showed that the proportion of stage C (T3) and stage D2 (M1) disease was 20% and 32%, respectively, in 1985 compared with 10% and 11% in 1994. 6 These data indicate that a signi®cant proportion of men still present with metastatic disease or progress to metastatic disease after de®nitive treatment, and suggest the need for an effective and durable initial treatment of M1 disease.
In 1977, Bracci ®rst suggested that there might be an advantage in patients with advanced disease from the addition of an antiandrogen (cyproterone acetate (CPA)) to castration in terms of survival. 7 The European Organization for Research and Treatment of Cancer (EORTC) carried out the ®rst randomized trial of orchiectomy vs orchiectomy plus CPA vs diethylstilbestrol. This trial (EORTC 30805), starting in 1980 and involving 339 evaluable patients, showed no bene®t for this form of additional antiandrogen therapy. 8 In 1982, some remarkable results from Labrie and coworkers seemed to show that the addition of a nonsteroidal antiandrogen to castration (medical or surgical) could make a signi®cant impact on the disease process. 9 Lengthening of both the time to progression and overall and cancer-speci®c survival was noted. A number of terms have been applied to this therapeutic regimen, including combined, maximum, complete or total androgen blockade, complete hormonal therapy, maximum androgen deprivation and total androgen ablation.
Hormonal control of prostate growth
In order to stimulate prostate growth, the adrenal steroid precursors DHEA, DHEA sulphate and/or androstenedione must be taken up by the prostatic tissue and metabolized locally into the active androgens, testosterone and DHT ( Figure 1 ). The formation of DHT from adrenal androgens involves four enzymes: sulphatase; 3b-hydroxysteroid dehydrogenase/D 5 ± D 4 isomerase (3b-HSD); 17b-hydroxysteroid dehydrogenase (17b-HSD); and 5a reductase. 10 The genes encoding these enzymes are expressed in human prostatic tissue, explaining the high level of DHT formation in the prostate.
Fundamental to the hormone responsiveness of the prostate gland is the inter-relationship between signalling pathways, those effecting a biological response through steroid receptor proteins and those activated by the binding of the peptide growth regulatory factors to cell membrane receptors. The androgenic action of DHT depends on the speci®c binding of the steroid ligand to the nuclear androgen receptor (AR). The androgenic signal is then transmitted through the DHT-AR complex to the genome by its association with nucleotide sequences on the DNA Ð the androgen response elements (AREs), Ð sites upstream of and adjacent to the responsive gene (Figure 2 ). The interaction between DHT ± AR and the AREs modulates the transcription of particular genes, either activating or suppressing gene expression.
The DHT ± AR complex appears to modify the spatial orientation of the DNA strands to facilitate the easier access of other transcription factors to the enhancer sequences of the gene promoter region. Such factors as the Fos and Jun proteins, encoded by the c-fos and c-jun proto-oncogenes, are intimately concerned in growth regulation. The Fos/Jun heterodimer binds to another recogition site on DNA (AP-1) involving the nucleotide sequence TGACTCA. The relative positioning of these regulatory sequences can result in competition or cooperation with the DHT ± AR complex. The Fos and Jun proteins can auto-repress the expression of their own genes, which are also positively regulated by epidermal growth factor (EGF) and the keratinocyte growth factor (KGF) (Figure 2 ). 11 In primary prostatic tumours, EGF-receptor immunostaining was localized in the epithelial and TGF-a staining in the stromal cells, while co-expression of the ligand and the receptor by epithelial tumour cells was observed in nearly 80% of tissue specimens of hormone-refractory metastases. These ®ndings suggest that in primary tumours a paracrine pattern of growth factor stimulation predominates, whereas in androgen-independent disease, there is a shift towards an autocrine stimulatory loop.
In contrast to the growth factors that stimulate prostatic growth, TGFs-b are bifunctional regulators that are thought to play the major role as growth inhibitors in the prostate. They are key regulators in programmed cell death and play a role in tumour ± host interaction.
Clinical review
To test the theory that maximum androgen blockade (MAB) is superior to conventional treatment of prostate cancer, ie castration alone, a large number of controlled trials have been conducted. The MAB arm of such trials generally includes one of four antiandrogens: bicalutamide,¯utamide, nilutamide or CPA. Castration within the trials takes the form of bilateral orchiectomy or a 
Trials showing no advantage for MAB
The trials that failed to show an advantage of MAB over monotherapy in terms of survival in metastatic disease are listed in Table 1 . 4,8,12 ± 18 It has been suggested that many of the studies that failed to show an advantage had inadequate statistical power because insuf®cient numbers of patients were included. 19 To detect a statistically signi®cant difference in survival between treatments, which was thought to be clinically relevant, it was proposed that a minimum of 300 patients should be included in each treatment arm. 20 Another criticism of these trials is that the duration of follow-up was insuf®cient. For example, the EORTC 30853 and the Anandron Study Group studies showed no signi®cant survival advantage on primary analysis, but after a longer follow-up the difference between the treatments was signi®cant in favour of MAB. 21 ± 25 Nevertheless, one large-scale randomized trial (NCI-INT 0105; n 1382) with a 5 y follow-up comparing bilateral orchiectomy with and without the addition of¯utamide did not show a survival advantage for MAB in terms of time to progression or survival. 16 One large-scale meta-analysis of 22 randomized trials on MAB involving 5710 patients with advanced cancer has been published; the median follow-up time was 40 months. 25 The overall mortality among patients in the castration group (orchiectomy or LHRHa) was 58.4% compared with 56.3% in the MAB group; 5 y survival was 22.8% and 26.2%, respectively. No survival advantage for MAB in metastatic disease was shown, although patients with minimal disease may have bene®ted. This analysis has been criticized on a number of points, including the fact that three different antiandrogens were involved and their effects may not be comparable. In addition, the follow-up period may be too short to see an effect on cancer mortality and 5 y survival may not be a suitable endpoint for a disease with a median survival of only 3 y.
More recent analyses have shown that if only the trials involving non-steroidal antiandrogens are analysed there is a borderline signi®cant difference in favour of MAB. 26 ± 29 For CPA the reverse is true. 25 When all 27 studies with the four different antiandrogens are examined, the signi®cance disappears. Other meta-analyses have been carried out by Caubet, 26 Klotz, 27 Debruyne 28 and Bennett, 29 but are less complete than the Prostate Cancer Trialists' Collaborative Group 25 and often look at trials which by themselves are too small to be signi®cant. 
Trials showing an advantage for MAB
Three randomized trials have demonstrated a survival advantage for MAB in metastatic prostate cancer. 22, 24, 30 The Southwest Oncology Group (SWOG-INT 0036) compared leuprolide plus¯utamide with leuprolide plus placebo. 30 The EORTC-30853 study compared goserelin acetate plus¯utamide with bilateral orchiectomy. 22 The third study by the Anandron Study Group compared bilateral orchiectomy plus nilutamide with bilateral orchiectomy. 24 In all three studies, median time to progression and median time of overall survival were longer in the MAB arm (Table 2 ). This reached statistical signi®cance in the SWOG-INT 0036 trial. Nevertheless, the use of this treatment regimen in metastatic prostate cancer remains controversial.
Quality of life and prognostic factors
Since MAB is considered a palliative treatment, healthrelated quality of life is an important issue. The ®rst study to examine this factor was Intergroup Study 0105, which compared orchiectomy with and without¯utamide. 16 The tolerability of¯utamide was shown to be low. In particular,¯utamide-related diarrhoea was signi®cantly more common under MAB. Furthermore, gynaecomastia led to a deterioration in body image. The emotional dimension to the side-effects of MAB began at 3 months. The Symptom Distress Scale, which assesses the effects of adverse events, clearly showed an impairment of quality of life. It could be argued that employing an antiandrogen such as bicalutamide, which is better tolerated, might result in a better quality of life. 31 Rosendahl et al 32 tried to assess the various quality of life domains using utility scores. In comparing MAB with orchiectomy, the quality of life adjusted survival rate was 5.2 months greater with MAB. This study was based on the EORTC study 30853. Another important aspect is the assessment of prognostic factors in patients with bone metastases at the start of treatment. It has been shown by Sylvester et al 33 that haemoglobin, alkaline phosphatase, pain score and Tstage are of prognostic relevance. Patients with a good prognostic score bene®t with MAB treatment compared with monotherapy; the risk of death with MAB is reduced by 39% in patients with a good prognostic score compared with a 13% reduction in those with a poor score. 33 Such prognostic factors may open the door for the future use of MAB in a treatment management programme. In addition, by measuring the PSA dynamic following MAB treatment from 4 weeks, one can predict which tumours have good prognosis and which do not.
Clinical situations for MAB use
It has been suggested that three clinical situations exist for the use of MAB in advanced prostate cancer:
in the severely symptomatic patient with metastatic disease; as neoadjuvant therapy prior to radiotherapy; for the prevention of¯are associated with the use of an LHRHa as monotherapy.
In order to de®ne further the future role of MAB a group of prostate cancer experts presented a series of real cases for discussion. Some of these cases fall into the three patient groups suggested above, while others do not, showing that the debate over the precise role of MAB in the management schema of prostate cancer is not yet over.
Case studies based on established indications MAB in symptomatic disease
Case one. This case involves the use of MAB as endocrine therapy in a patient with severely symptomatic metastatic disease. The 74-y-old patient was referred from his general physician with severe bone pain, especially in his lower back, left hip and left thigh. Digital rectal examination (DRE) was suggestive of prostate cancer. At referral, the patient was being treated with morphine sulphate 60 mg three times a day and a non-steroidal anti-in¯am-matory for the bone pain. The patient had a history of mild arteriosclerotic heart disease, but was otherwise healthy. However, 2 months before referral, he suffered a deep venous thrombosis in the left leg and was started on anticoagulant therapy. Investigations were carried out and con®rmed the presence of a large T4 prostate cancer. The PSA level was 476 ng/ml and the alkaline phosphatase level was four times the upper normal level. Two biopsies were carried out transrectally with ultrasound guidance and both showed poorly differentiated prostatic adenocarcinoma (Gleason 8). Ultrasound showed a large, poorly delineated prostate with no zonal echo pattern, which was suggestive of diffuse carcinoma. Multiple hot spots in the axial skeleton, pelvic region, ribs and left femur were revealed by the bone scan (Soloway score 2). The patient's disease stage and grade were T4 Nx M1 G3 (Gleason 8).
MAB treatment was recommended. The patient opted for bilateral orchiectomy, which was convenient, as coumarin anticoagulation therapy in the department was considered a relative contraindication for LHRHa therapy (due to the risk of haematoma formation after injection). This was combined with a non-steroidal antiandrogen, which was started immediately following the transrectal biopsy. After 3 months, the patient was free of pain and had stopped the analgesics; his PSA level was 2.4 ng/ml. MAB treatment is ongoing and the patient is seen every 3 months. The deep venous thrombosis in the patient's left leg was most likely caused by impaired lymphatic drainage due to pelvic lymph node metastases. When the PSA level eventually begins to climb, as ®rst evidence of disease progression, the antiandrogen will be discontinued in the hope that the patient will bene®t from an antiandrogen withdrawal response.
Commentary. In combination with orchiectomy, just as with LHRHa, the antiandrogen leads to a more rapid improvement in symptoms, although there is no evidence of a survival advantage for the combination over simple castration.
Case two. This case is a 68-y-old man who was previously ®t and active and who presented with a 1 y history of a weak urinary stream, postmicturition dribbling and nocturia. Six months before presentation he had begun to experience episodes of backache and pain in his thighs, which had got progressively worse and were now constant. The patient's PSA level was 1480 ng/ml and alkaline phosphatase 300 ng/ml. DRE was consistent with a T3 ± 4 carcinoma. Three biopsies were performed, left and right, and all were positive with Gleason score 3 4. The ultrasound con®rmed the presence of extensive capsular breakthrough and involvement of the pelvic oor. A bone scan revealed multiple hot spots in the lumbar spine, pelvis and in a number of ribs. The changes in the pelvis and lumbar spine were not associated with obvious signs of arthritis on plain X-rays. The patient's disease stage was diagnosed as T4 (?b) G3 N? M .
Given the patient's widespread symptomatic, metastatic disease, he was started on a non-steroidal antiandrogen after surgical castration. Six months later, his PSA had fallen to 10 ng/ml and he was asymptomatic, not requiring painkillers and rising only once at night to pass urine. Three months later, however, his PSA began to rise and the antiandrogen was stopped. He enjoyed further symptomatic relief for another 3 months before the PSA started to rise again. When the patient's PSA level had risen to above 100 ng/ml another non-steroidal antiandrogen was administered and the patient's PSA level stabilized for a period of 4 months, but again began to rise. The patient is currently on estramustine, 560 mg/day and, although his PSA continues to rise, he enjoys some symptomatic relief.
Commentary. Patients with markedly elevated PSA and extensive metastatic disease, especially when symptomatic, bene®t from MAB. The principal advantage of the use of MAB in this patient is the immediate removal of androgen stimulation to his tumour. His subsequent progress con®rms the bene®t of antiandrogen withdrawal followed by response to a second (different) antiandrogen.
Neoadjuvant MAB prior to radiotherapy
Case three. This case is a Japanese businessman, aged 62 y, who was given a diagnosis of localized prostate cancer. As he travelled frequently between Tokyo and Amsterdam, he sought a second opinion 1 month later in Amsterdam. In Tokyo, he had presented with mild symptoms of bladder out¯ow obstruction. Rectal examination showed an irregular prostate and subsequent biopsies revealed a T3, Gleason 6 tumour on the right side. In Amsterdam, the DRE con®rmed the presence of a tumour, which seemed to have broken through the capsule. PSA level was 76 ng/ml and biopsies con®rmed Gleason 3 3, positive on the right side. The ultrasound showed capsule breakthrough on the right-hand side; bone scans were negative. Tumour stage was determined as T3 G2 Nx M0. In view of the high PSA level, the lymph nodes were examined by laparoscopic lymph node dissection; 13 nodes were removed, seven from the right side and six from the left. No evidence of tumour was found.
The patient was immediately started on MAB treatment with an antiandrogen and an LHRHa, before receiving a full course of external beam radiotherapy after 2 months. The hormone therapy continued for 2 weeks after the radiotherapy had been completed. One year after treatment the only symptom the patient has is occasional blood loss with defaecation. His urinary symptoms have disappeared completely and his PSA is less than 0.3 ng/ml. A recent DRE indicated a prostate nodule reduced in size, with no further extension outside the capsule. Apart from blood on the ®nger stall, no other abnormality was found.
Commentary. Certain studies indicate increased progression-free survival in patients treated primarily with radiotherapy who receive MAB or LHRHa alone in a neoadjuvant or adjuvant setting. 34, 35 One study by Pilepich and co-workers, 36 however, only showed an improvement in time to disease progression without an improvement in overall survival.
Case four. This case is a 62-y-old patient who has had a regular physical examination for the last 12 y. His PSA level has¯uctuated between 2.5 and 3.0 ng/ml for some time until it rose to 4.9 ng/ml. His urologist performed a DRE and felt that the prostate was ®rm in the mid-line, mobile and non-tender; size was estimated as 25 g. The patient underwent a transrectal ultrasound guided biopsy of the prostate. Two of the ®ve biopsies indicated Gleason 7 adenocarcinoma; bone scan was normal.
Various treatment alternatives were discussed at length with the patient and he chose to proceed with a total prostatectomy. Pathology revealed a Gleason score 9 ductal adenocarcinoma. The tumour began just posterior to the urethra and extended primarily in the right side of the prostate, all the way to the bladder neck. It involved approximately 20% of the cut surface of the prostate and appeared in lymphatics in the pericapsular adipose tissue. The inked resection margins were free of malignancy, as were the seminal vesicles and all of the removed lymph nodes.
The patient was followed up regularly with DRE and PSA monitoring. Six months after his operation his PSA level was 0.1 ng/ml, at 10 months it was 0.08 ng/ml at at 16 months it was 0.11 ng/ml. It remained at this level until 12 months postoperatively, when it registered at 0.2 ng/ml. At the same time, a slight alteration in the prostate fossa was noted. Five months after this, the PSA was 0.13 ng/ml and once again there was a slight change in the symmetry of the prostatic fossa with a suggestion of a very small nodule. Four months later, the PSA had risen to 0.3 ng/ml.
The likely local recurrence based on the slight rise in PSA and the abnormal DRE was discussed with the patient. He agreed to androgen deprivation followed by external beam radiotherapy. He was started on a LHRHa and a non-steroidal antiandrogen and after 3 months underwent 6480 cGY radiation therapy to a small ®eld in the pelvis, concentrating on the prostate bed. The androgen deprivation was discontinued at the conclusion of the radiation therapy. Currently, at 36 months the patient's general health is excellent, his PSA is undetectable and DRE is normal.
Commentary. Adjuvant hormonal therapy with radiotherapy has been shown to result in increased survival in patients with localized prostate cancer. 34 In this case, the local recurrence could be considered as localized disease.
MAB for prevention of¯are
Case ®ve. Case ®ve is a 56-y-old Afro-American who presented with a rising serum PSA over a 6-month period. He avoided biopsy until his PSA increased to 190 ng/ml. He had no bladder outlet obstructive symptoms, abdominal pain,¯ank or back pain. A DRE revealed bilateral induration with extra capsular extension at the left base. Ultrasound and sextant biopsies showed four out of six positive biopsies for a Gleason 3 4 7. A computed tomography scan demonstrated enlarged left-sided pelvic and retroperitoneal nodes consistent with metastatic disease. No bony metastases were found on bone scan. The patient was staged as T3 N3 M0, moderate to poorly differentiated cancer.
It was decided to start the patient on androgen ablation therapy with an LHRHa, after a 1 month preliminary treatment period with a non-steroidal antiandrogen to protect against¯are. Over the next year, the patient's PSA level decreased to a nadir of 3.6 ng/ml before starting to rise again over a period of 4 months to 5 ng/ml and then 8 ng/ml. To counter this, a non-steroidal antiandrogen was administered again and this resulted in a fall in PSA level to 3.5 ng/ml, then 2.6 ng/ml and a new nadir of 0.8 ng/ml. His PSA level has remained stable for 6 months.
Commentary. Antiandrogens have proven ef®cacy in preventing¯are reaction when initiating LHRHa therapy. There is extensive evidence to suggest that¯are protection should be used in all metastatic prostate cancer patients when beginning LHRHa therapy. 37, 38 Case six. Case six is a 62-y-old man, otherwise healthy, who was referred with lower urinary tract symptoms (LUTS) which had increased in severity during the last 6 months. DRE revealed a hard, enlarged, irregular prostate, indicative of cancer. The patient had no pain or any other symptoms suggestive of disseminated disease. The patient's PSA level was 197 ng/ml and his alkaline phosphatase level was normal. Three out of the three biopsies performed were positive for moderately well-differentiated prostatic adenocarcinoma (Gleason score 6). Ultrasound showed a poorly delineated prostate with no distinguishable zonal anatomy. Bone scan revealed multiple hot spots in the ribs, spine and pelvis ( Figure 3 ). His chest X-ray was normal. Disease stage and grade was diagnosed as T3 Nx M1 G2 (Gleason 6).
The patient was recommended to start endocrine therapy with an LHRHa. For¯are protection, the patient received an antiandrogen for 1 month with initiation of the ®rst LHRHa depot subcutaneously after 3 days. After 3 months the patient's PSA level had been reduced to 3.5 ng/ml and the LUTS had improved. Nonetheless, the patient underwent a transurethral resection of the prostate (TURP) with a satisfactory result. LHRHa therapy is continuing.
Commentary. Even though there is no solid evidence that prostate cancer may be disseminated by TURP, a number of departments avoid TURP in patients where endocrine therapy is indicated until such therapy has been administered for at least 2 months without relief of obstruction. 
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Case studies outside the main circumstances Neoadjuvant MAB prior to surgery
On presentation, the 58-y-old patient was asymptomatic from a genitourinary point of view and had no history of obstructive or irritative voiding symptoms. His past medical history was otherwise non-contributory and there was no family history of prostate cancer. Physical examination revealed an indurated left lobe of the prostate cancer gland consistent with a stage T2b carcinoma. Ultrasound showed three out of six positive biopsies along the left lobe of the prostate gland, giving a Gleason 3 4 7, moderate to poorly differentiated prostate cancer. Serum PSA was 14 ng/ml. The patient was treated with an LHRHa plus a nonsteroidal antiandrogen. Eight months after hormone therapy, his PSA level was 0.1 ng/ml. He underwent an uneventful radical prostatectomy and pathology revealed a small volume, organ-con®ned tumour. The patient is now 2 y post surgery with an undetectable serum PSA of less than 0.1 ng/ml. Serum testosterone was within normal limits by 3 months post surgery.
Commentary. Young men with high-risk, clinically con®ned prostate cancers have an approximately 40 ± 50% chance of positive margins and a similar risk for PSA recurrence. The use of 3 months of neoadjuvant hormone therapy reduces the risk of positive margins by 50%, while longer-term neoadjuvant hormone therapy, as used with this patient, reduces the risk to the 5% range. The effects of long-term neoadjuvant hormone therapy on PSA recurrence rates is under investigation. This patient was recommended to receive neoadjuvant hormone therapy prior to radical prostatectomy due to his young age and high-risk tumour, although the survival bene®t for this form of therapy has not yet been proven.
Intermittent androgen ablation
This 74-y-old patient had a PSA of 46 ng/ml and DRE revealed a small prostate, approximately 25 g in size. The apex was diffusely ®rm and the palpable abnormality appeared to extend to the edge of the prostate. The patient had a history of polio and deep venous thrombosis. He had suffered a fracture in the right hip and had dif®culty walking. It was considered that the patient had a clinical stage T3a adenocarcinoma of the prostate. A bone scan was negative for metastatic disease, although there were areas of increased uptake, which were considered consistent with arthritis.
On the basis of the PSA level, it was agreed that the best option would be MAB with an LHRHa and a nonsteroidal antiandrogen. The patient's PSA level fell to below 0.2 ng/ml at 6 months. The following year, the patient complained of being somewhat more lethargic than normal. The continuation of the MAB treatment was discussed and the patient elected to discontinue the antiandrogen and continue with the LHRHa as monotherapy. A few months later, further discussions about treatment took place. The hot¯ushes were bothering the patient and he discontinued the LHRHa. His PSA level was 2.0 ng/ml, which then rose to 8.4 ng/ml at which point androgen deprivation was re-initiated. Twelve months later, the PSA had declined to 0 and androgen deprivation was discontinued. It was restarted when the PSA level rose to 8.1 ng/ml during the next year. This cycle repeated itself over the next 2 y. A bone scan continues to be negative for metastatic disease. At last measurement, the patient's PSA was 0.1 ng/ml. Each time the LHRHa therapy was re-initiated, the antiandrogen was given for 1 month.
Commentary. The rationale behind intermittent androgen suppression (IAS) is based on the hypothesis that tumour cells surviving androgen withdrawal are forced along a differentiation pathway by androgen replacement, permitting restored apoptotic potential and delayed progression to androgen independence. Observations from accumulating experience in phase II studies suggest that IAS is a feasible treatment option for men with advanced or recurrent prostate cancer and does not appear to have negative impact on time to progression or survival compared with continuous combined therapy. 39 IAS improves quality of life by permitting recovery of libido and potency, increasing energy levels and enhancing sense of well-being during off-treatment periods. However, patients should be advised that IAS remains investigational and some men may be harmed by this dose-reduction regimen. Phase III randomized studies are underway to assess accurately the effects of IAS on survival.
If this patient's life expectancy exceeds 5 ± 7 y, he may bene®t from the addition of radiation therapy at the completion of his third treatment cycle, especially if his DRE shows signs of local progression off therapy. This may reduce the risk for local progression and symptoms, and prolong the duration of each`off' treatment cycle.
Small volume metastatic disease
This 69-y-old man presented with voiding dif®culties, notable a poor stream and nocturia; peak¯ow rate was 7 ml/s. He had a history of a hemicolectomy for Dukes A colonic carcinoma 5 y previously and two myocardial infarcts since then. He underwent a triple vessel coronary artery bypass graft 4 months prior to the ®rst urological assessment.
The DRE revealed a nodule in the right lateral lobe (1 cm); PSA level was 17.2 ng/ml. Biopsy revealed adenocarcinoma (Gleason 3 4) on the right side of the prostate and benign prostatic hyperplasia on the left. The patient's ultrasound showed a 1.5 cm hypoechoic lesion at the periphery of the right lateral lobe. Magnetic resonance imaging of the pelvis was unremarkable, although the primary lesion seemed to be intracapsular. No enlarged pelvic nodes were discovered and the bone scan was negative. Disease stage and grade was diagnosed as pT2a M0 N0 (Gleason score 7).
The patient underwent a laparoscopic pelvic lymphadenectomy, which demonstrated positive micrometastatic disease in two nodes on the right side. This staging laparoscopy was undertaken with an intention to use radiotherapy, but this was now contraindicated (new staging pT2a M0 N1). The patient had a channel TURP and a bilateral orchiectomy with a dramatic improvement in¯ow rate. A non-steroidal antiandrogen was added to his regime to provide a potential for MAB. The patient's PSA level was`0.1 ng/ml for 6 y after treatment. Neither biopsies nor scans have subsequently been required. Use of MAB and TURP in this patient has led to a 6 y period free of biochemical recurrence.
Commentary. A balance of evidence suggests that MAB may be a superior treatment to monotherapy in patients with low volume metastasis. Consequently, in patients with only micrometastatic disease, there may be the opportunity for an even greater effect from MAB. To date, however, this remains a speculative, but reasonable, scienti®c assumption. This patient made an informed decision to undergo adjuvant hormonal treatment. He felt that if there was any chance that early MAB might be superior to monotherapy (delayed or early), when the side-effects were not dissimilar, his choice would be aǹ insurance' policy.
Treatment algorithm
A proposed treatment algorithm for patients with advanced prostate cancer is shown in Figure 4 .
Conclusion
Currently, the widespread use of MAB is debatable on the basis of clinical data. However, there does appear to be a role for MAB in advanced prostate cancer for three clinical situations: in symptomatic disease; as neoadjuvant therapy prior to radiotherapy; and for the prevention of¯are. MAB may ®t into an algorithm of`progressive' step-up therapy, in which the tailoring of hormonal therapy to individual patients and their tumours (sequentially) may improve survival, as well as further clarify the role of MAB (Table 3) .
Patients who are considered to be suitable for hormonal therapy could initially receive minimal therapy with a Figure 4 Treatment algorithm for advanced prostate cancer. MAB maximum androgen blockade; RT radiotherapy; NSAA nonsteroidal antiandrogen; SAA steroidal antiandrogen; CPA cyproterone acetate; LHRHa luteinising hormone releasing hormone agonist. 
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Insensitive to all hormonal Castrate levels of testosterone Androgen-independent, endocrine independent manipulation Maximum androgen blockade DWW Newling non-steroidal or a steroidal antiandrogen. There is possibly a theoretical reason to offer a steroidal antiandrogen as primary therapy in patients with small volume metastatic disease, since it is a form of MAB. Whether this is justi®ed will be shown by the results of the EORTC study 30892, involving¯utamide vs CPA in asymptomatic patients with metastatic prostate cancer.
On progression, an LHRHa may be given or surgical castration carried out. After this form of MAB the next step could be withdrawal of the antiandrogen. If this produces no response, or when that response is exhausted, the use of oestrogens or estracyt may be recommended, making use of the additional cytotoxic effect of these compounds. Using PSA as the method of monitoring both response and relapse, new therapies can be introduced before a patient develops complications such as uraemia, spinal cord compression or pain.
As an earlier diagnosis is becoming more common in advanced disease, more patients will be diagnosed with a lower tumour burden and a better performance status. It is possible that these patients will bene®t from early MAB, in which case there may be a signi®cant impact on the mortality rate in patients with advanced prostate cancer. A more sensible appreciation of the hormonal environment of patients and their tumours will lead to a more systematic and logical use of hormonal therapy, including MAB.
